Mechanism and Clinical Implications of Isoproterenol
Pharmacodynamic Profile
- Isoproterenol is a non‑selective β‑adrenergic agonist that stimulates both β₁ and β₂ receptors throughout the body – this underlies its combined cardiac and vascular actions. 1
- β₁‑mediated cardiac effects: the drug enhances sinus node automaticity and sino‑atrial conduction, producing a positive chronotropic response (increased heart rate). 1
- β₁‑mediated cardiac effects: it increases myocardial contractility (positive inotropy), thereby raising cardiac output. 1
- β₁‑mediated cardiac effects: it improves atrioventricular nodal conduction, facilitating AV‑node function. 1
Pulmonary Vascular Effects
- Isoproterenol induces vasodilation of the pulmonary artery, which can lower pulmonary vascular resistance. 2
Pharmacokinetic Considerations
- The intravenous elimination half‑life of isoproterenol is extremely short (approximately 2–5 minutes), necessitating continuous infusion to maintain therapeutic effect. 3
Critical Clinical Implications
Oxygen Demand–Supply Mismatch
- The drug raises myocardial oxygen demand via β₁‑mediated increases in heart rate and contractility while simultaneously reducing coronary perfusion through β₂‑mediated vasodilation, creating a potentially hazardous mismatch in patients with coronary ischemia. [4][2]
- Consequently, isoproterenol should be avoided in clinical situations where coronary ischemia is a concern. 4
Hemodynamic Profile
- The combination of increased cardiac work (β₁ effects) and reduced afterload (β₂‑mediated peripheral vasodilation) makes isoproterenol useful for treating bradycardia but problematic in hypotensive states that require peripheral vasoconstriction. 2